Pneumagen Company

Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.

Total Funding: £4M
Headquarters: Saint Andrews, Fife, United Kingdom
Employee Number: 1-10
Estimated Revenue: $1M to $10M
Last Funding Type: Venture - Series Unknown
Technology: Anti-infective Drugs
Investor Type: For Profit
Investors Number: 2
Founded Date: 2016
Industry: PharmTech